LBi001-B
iLB-268bfs9, PH-BL-001 Clone 9
iPSC line
The cell line is not available.
General#
Cell Line |
|
| hPSCreg Name | LBi001-B |
| Alternative name(s) |
iLB-268bfs9, PH-BL-001 Clone 9
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Notes | CD33 medium risk Alzheimer disease TREM2-/- CD33+/- (TREM2WT/WT, CD33M/m) |
Provider |
|
| Depositor | Life & Brain GmbH (LB) |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
| Derivation country | Germany |
External Databases |
|
| hPSCreg | LBi001-B |
| BioSamples | SAMEA111454103 |
| CLO | CLO_0104382 |
| Cellosaurus | CVCL_C6QI |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: not allowed
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 75-79 |
| Ethnicity | White European |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Donor Relations |
|
| Other cell lines of this donor |
|
External Databases (Donor) |
|
| BioSamples | SAMEA111454101 |
hIPSC Derivation#
General |
|
| Source cell type |
erythroid progenitor cellCommitted, erythroid stem cells derived from myeloid stem cells. The progenitor cells develop in two phases: erythroid burst-forming units (bfu-e) followed by erythroid colony-forming units (cfu-e). Bfu-e differentiate into cfu-e on stimulation by erythropoietin, and then further differentiate into erythroblasts when stimulated by other factors.
|
| Source cell origin |
BloodA liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Age of donor (at collection) | 75-79 |
| Collected in | 2018 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 6 % |
| Medium |
Other medium:
Base medium: StemMACS™ iPS-Brew XF, Basal Medium
Main protein source: StemMACS™ iPS Brew XF, 50x Supplement Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
Morphology pictures
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal 46XX
|
Other Genotyping (Cell Line) |
|